Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02085421 · ClinicalTrials.gov registry record · NA
Transcranial Direct Current Stimulation and Cognitive Remediation Therapy for Psychosis
A NA study, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT02085421: Completed NA study, sponsored by University of Minnesota.
NCT02085421 is a NA study that has completed, run by University of Minnesota. The registered enrollment target is 33 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02085421, a NA study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
The proposed pilot study is a randomized controlled study to assess effectiveness of transcranial direct current stimulation (tDCS) to enhance cognitive remediation therapy in patients with psychotic disorders. tDCS. Patients will be randomized into two arms: active tDCS vs. sham tDCS. The active tDCS will be applied at a current of 1-2 mA (milliamperes) via two saline soaked electrode sponges (3 cm x 4.5 cm) applied to the side of the head. The investigators hypothesis is that the use of tDCS will enhance the improvement seen with cognitive remediation therapy.
Primary Outcome
Clinician-administered neurocognitive battery that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. Brief Assessment of Cognition in Schizophrenia (BACS) - post training composite z-score range Arm 1 = -2.46 - 2.24 range Arm 2 = -7.67 - 0.83 Higher scores represent better cognitive performance. The BAC APP composite z-score is calculated as the sum of the subscale z-scores (i.e., verbal memory, digit sequencing
Interventions
- DEVICE tDCS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-03-14 |
| Est. Completion | 2023-02-09 |
| Phase | NA |
What the finished NCT02085421 record still lists
NCT02085421 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which tDCS is the first listed.
NCT02085421 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02085421 about?
NCT02085421 is a clinical study titled "Transcranial Direct Current Stimulation and Cognitive Remediation Therapy for Psychosis". The proposed pilot study is a randomized controlled study to assess effectiveness of transcranial direct current stimulation (tDCS) to enhance cognitive remediation therapy in patients with psychotic disorders. tDCS. Patients will be randomized into two arms: active tDCS vs. sham tDCS. The active tD...
What is the current status of trial NCT02085421?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2019-03-14. Estimated completion is 2023-02-09.
What interventions are being tested in trial NCT02085421?
The interventions under investigation include: tDCS (DEVICE).
Who is sponsoring clinical trial NCT02085421?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02085421's enrollment target sits among peer trials
33 1574th of 2000 higher than 423 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI